These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31782938)

  • 21. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A conditional error function approach for subgroup selection in adaptive clinical trials.
    Friede T; Parsons N; Stallard N
    Stat Med; 2012 Dec; 31(30):4309-20. PubMed ID: 22865774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian population finding with biomarkers in a randomized clinical trial.
    Morita S; Müller P
    Biometrics; 2017 Dec; 73(4):1355-1365. PubMed ID: 28257141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarker enrichment considerations in oncology early development single-arm studies.
    Tian H; Liu K
    J Biopharm Stat; 2018; 28(2):282-291. PubMed ID: 28934023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.
    Schnell PM; Tang Q; Offen WW; Carlin BP
    Biometrics; 2016 Dec; 72(4):1026-1036. PubMed ID: 27159131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
    Uozumi R; Yada S; Kawaguchi A
    BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive enrichment trials: What are the benefits?
    Burnett T; Jennison C
    Stat Med; 2021 Feb; 40(3):690-711. PubMed ID: 33244786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variance prior specification for a basket trial design using Bayesian hierarchical modeling.
    Cunanan KM; Iasonos A; Shen R; Gönen M
    Clin Trials; 2019 Apr; 16(2):142-153. PubMed ID: 30526008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.
    Park Y; Liu S; Thall PF; Yuan Y
    Biometrics; 2022 Mar; 78(1):60-71. PubMed ID: 33438761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptive Enrichment Designs in Clinical Trials.
    Thall PF
    Annu Rev Stat Appl; 2021 Mar; 8(1):393-411. PubMed ID: 36212769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian adaptive design for biomarker trials with linked treatments.
    Wason JM; Abraham JE; Baird RD; Gournaris I; Vallier AL; Brenton JD; Earl HM; Mander AP
    Br J Cancer; 2015 Sep; 113(5):699-705. PubMed ID: 26263479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials.
    Xu Y; Trippa L; Müller P; Ji Y
    Stat Biosci; 2016 Jun; 8(1):159-180. PubMed ID: 27617041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing and analyzing clinical trials for personalized medicine via Bayesian models.
    Zhang C; Mayo MS; Wick JA; Gajewski BJ
    Pharm Stat; 2021 May; 20(3):573-596. PubMed ID: 33463906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A nonparametric Bayesian basket trial design.
    Xu Y; Müller P; Tsimberidou AM; Berry D
    Biom J; 2019 Sep; 61(5):1160-1174. PubMed ID: 29808479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time-trend impact on treatment estimation in two-arm clinical trials with a binary outcome and Bayesian response adaptive randomization.
    Jiang Y; Zhao W; Durkalski-Mauldin V
    J Biopharm Stat; 2020; 30(1):69-88. PubMed ID: 31017843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.